Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stan L Block

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
The Pediatric Infectious Disease Journal|May 9, 2007
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trialKeith S Reisinger, Stan L Block, Eduardo Lazcano-Ponce, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Pediatrics|August 20, 2014
Long-term study of a quadrivalent human papillomavirus vaccineDaron Ferris, Rudiwilai Samakoses, Stan L Block, et al.
JAMA|July 25, 2023
Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical TrialNader Shaikh, Alejandro Hoberman, Timothy R Shope, et al.
The Pediatric Infectious Disease Journal|June 25, 2015
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015Michelle Vichnin, Paolo Bonanni, Nicola P Klein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2016
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world ExperienceSuzanne M Garland, Susanne K Kjaer, Nubia Muñoz, et al.
The Lancet. Infectious Diseases|September 6, 2020
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trialJudith Absalon, Nathan Segall, Stan L Block, et al.
Pediatrics|September 5, 2023
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and SafetyJaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, et al.
The New England Journal of Medicine|December 22, 2016
Shortened Antimicrobial Treatment for Acute Otitis Media in Young ChildrenAlejandro Hoberman, Jack L Paradise, Howard E Rockette, et al.
Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
The Pediatric Infectious Disease Journal|May 9, 2007
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trialKeith S Reisinger, Stan L Block, Eduardo Lazcano-Ponce, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Pediatrics|August 20, 2014
Long-term study of a quadrivalent human papillomavirus vaccineDaron Ferris, Rudiwilai Samakoses, Stan L Block, et al.
JAMA|July 25, 2023
Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical TrialNader Shaikh, Alejandro Hoberman, Timothy R Shope, et al.
The Pediatric Infectious Disease Journal|June 25, 2015
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015Michelle Vichnin, Paolo Bonanni, Nicola P Klein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2016
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world ExperienceSuzanne M Garland, Susanne K Kjaer, Nubia Muñoz, et al.
The Lancet. Infectious Diseases|September 6, 2020
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trialJudith Absalon, Nathan Segall, Stan L Block, et al.
Pediatrics|September 5, 2023
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and SafetyJaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, et al.
The New England Journal of Medicine|December 22, 2016
Shortened Antimicrobial Treatment for Acute Otitis Media in Young ChildrenAlejandro Hoberman, Jack L Paradise, Howard E Rockette, et al.
Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.
Pageof 12